Summary
- Pfizer and Moderna have submitted applications for two new COVID-19 vaccines targeting the JN.1 variant.
- Experts believe these vaccines would offer sufficient protection against the KP.2 and KP.3 variants.
- Australia is evaluating the approval of these new vaccines which are part of the FLiRT group.
- The approval process may take several months, but these vaccines are seen as a significant improvement.